Literature DB >> 26991037

Multiparametric whole-body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosis.

Shivani Ahlawat1, Asad Baig2, Jaishri O Blakeley3,4,5, Michael A Jacobs2, Laura M Fayad2,5,6.   

Abstract

PURPOSE: To describe the anatomic, functional, and metabolic characteristics of peripheral nerve sheath tumors (PNSTs) in patients with schwannomatosis (SWN) on whole-body magnetic resonance imaging (WB-MRI) (anatomic and functional imaging) and fluorine-18-fluorodeoxyglucose positron emission tomography / computed tomography (FDG-PET/CT) (metabolic imaging).
MATERIALS AND METHODS: WB-MRIs at 1.5T and 3.0T performed in 13 SWN subjects using short tau inversion recovery (STIR), T1 -weighted (T1 W), contrast-enhanced T1 W, and diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping and FDG-PET/CT were retrospectively reviewed. Two readers reviewed all imaging for the presence and character of peripheral lesions (size, imaging features, ADC values, and standardized uptake values [SUVmax ]) and ancillary findings. Descriptive statistics are reported.
RESULTS: In all, 153 index lesions were characterized in 13 patients on WB-MRI. Lesions were characterized as tumors (97% [149/153]) or cysts (3% [4/153]); 96% (143/149) PNSTs were solitary while 4% (6/149) were plexiform. The median size was 2.3 cm (range 1-24.3 cm). On T1 W, 99% (148/149) tumors were homogeneously isointense; on STIR, 81% (121/149) tumors were heterogeneously hyperintense; on postcontrast T1 W, 81% (100/123) tumors enhanced heterogeneously; on DWI, tumor ADC values (×10(-3) mm(2) /s) were variable (minimum ADC range 0.3-2.2, average ADC range 0.9-2.9). The median SUVmax was 6 (range 2.1-11.7) and 10 (2.7-15.3) on early and delayed imaging, respectively. Malignant degeneration was detected in 1% (1/149) with suspicious anatomic, functional, and metabolic characteristics. Ancillary findings included nerve root thickening (23% [3/13]) and spinal canal lesions (15% [2/13]).
CONCLUSION: Although the majority of the PNSTs in SWN are benign and solitary, PNSTs can be plexiform, enlarge over time, and, rarely, undergo malignant degeneration. Due to the high metabolic activity in benign PNSTs by FDG-PET/CT in SWN, WB-MRI with functional sequences maybe a more suitable technique for the assessment of disease burden, tumor characterization, and surveillance. J. MAGN. RESON. IMAGING 2016;44:794-803.
© 2016 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  FDG-PET/CT; apparent diffusion coefficient (ADC) mapping; diffusion weighted imaging; schwannomatosis; whole body MRI

Mesh:

Substances:

Year:  2016        PMID: 26991037      PMCID: PMC9182372          DOI: 10.1002/jmri.25236

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   5.119


  46 in total

1.  Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience.

Authors:  S Demehri; A Belzberg; J Blakeley; L M Fayad
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-24       Impact factor: 3.825

2.  MR imaging differentiation of benign and malignant peripheral nerve sheath tumors: use of the target sign.

Authors:  R Bhargava; D M Parham; O E Lasater; R S Chari; G Chen; B D Fletcher
Journal:  Pediatr Radiol       Date:  1997-02

3.  Imaging of ancient schwannoma.

Authors:  Kenichi Isobe; Tominaga Shimizu; Tsutomu Akahane; Hiroyuki Kato
Journal:  AJR Am J Roentgenol       Date:  2004-08       Impact factor: 3.959

4.  Clinical features of schwannomatosis: a retrospective analysis of 87 patients.

Authors:  Vanessa L Merker; Sonia Esparza; Miriam J Smith; Anat Stemmer-Rachamimov; Scott R Plotkin
Journal:  Oncologist       Date:  2012-08-27

5.  Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images.

Authors:  Wenli Cai; Ara Kassarjian; Miriam A Bredella; Gordon J Harris; Hiroyuki Yoshida; Victor F Mautner; Ralph Wenzel; Scott R Plotkin
Journal:  Radiology       Date:  2009-03       Impact factor: 11.105

6.  Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

Authors:  Victor-F Mautner; Florence A Asuagbor; Eva Dombi; Carsten Fünsterer; Lan Kluwe; Ralf Wenzel; Brigitte C Widemann; Jan M Friedman
Journal:  Neuro Oncol       Date:  2008-06-17       Impact factor: 12.300

7.  Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.

Authors:  Vanessa L Merker; Miriam A Bredella; Wenli Cai; Ara Kassarjian; Gordon J Harris; Alona Muzikansky; Rosa Nguyen; Victor F Mautner; Scott R Plotkin
Journal:  Am J Med Genet A       Date:  2014-03-24       Impact factor: 2.802

Review 8.  Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.

Authors:  Pamela L Wolters; Staci Martin; Vanessa L Merker; Kathy L Gardner; Cynthia M Hingtgen; James H Tonsgard; Elizabeth K Schorry; Andrea Baldwin
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910

9.  Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis.

Authors:  Miriam J Smith; Bertand Isidor; Christian Beetz; Simon G Williams; Sanjeev S Bhaskar; Wilfrid Richer; James O'Sullivan; Beverly Anderson; Sarah B Daly; Jill E Urquhart; Alan Fryer; Cecilie F Rustad; Samantha J Mills; Amir Samii; Daniel du Plessis; Dorothy Halliday; Sebastien Barbarot; Franck Bourdeaut; William G Newman; D Gareth Evans
Journal:  Neurology       Date:  2014-12-05       Impact factor: 9.910

10.  Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis.

Authors:  Laura M Fayad; Jaishri Blakeley; Scott Plotkin; Brigitte Widemann; Michael A Jacobs
Journal:  ISRN Radiol       Date:  2013-10-07
View more
  5 in total

1.  Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.

Authors:  Michael A Jacobs; Katarzyna J Macura; Atif Zaheer; Emmanuel S Antonarakis; Vered Stearns; Antonio C Wolff; Thorsten Feiweier; Ihab R Kamel; Richard L Wahl; Li Pan
Journal:  Acad Radiol       Date:  2018-04-04       Impact factor: 3.173

Review 2.  Diffusion weighted imaging demystified: the technique and potential clinical applications for soft tissue imaging.

Authors:  Shivani Ahlawat; Laura M Fayad
Journal:  Skeletal Radiol       Date:  2017-11-20       Impact factor: 2.199

3.  Tumor segmentation of whole-body magnetic resonance imaging in neurofibromatosis type 1 patients: tumor burden correlates.

Authors:  Michael A Heffler; Lu Q Le; Yin Xi; Avneesh Chhabra
Journal:  Skeletal Radiol       Date:  2016-11-04       Impact factor: 2.199

Review 4.  Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Authors:  Shivani Ahlawat; Jaishri O Blakeley; Shannon Langmead; Allan J Belzberg; Laura M Fayad
Journal:  Skeletal Radiol       Date:  2019-08-08       Impact factor: 2.199

5.  [18F]FDG Positron emission tomography with whole body magnetic resonance imaging ([18F]FDG-PET/MRI) as a diagnosis tool in Schwannomatosis.

Authors:  I Gallais Sérézal; S Ferkal; L Lerman; S Mulé; B Funalot; P Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2021-01-28       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.